Cytokinetics (CYTK) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free CYTK Stock Alerts $48.51 -0.61 (-1.24%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 4:16 AM | americanbankingnews.comTruist Financial Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $70.00May 31 at 3:44 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) PT Lowered to $78.00 at JMP SecuritiesMay 30 at 2:56 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) PT Lowered to $78.00May 29 at 4:00 PM | globenewswire.comCytokinetics to Participate in June Investor ConferencesMay 29 at 1:56 PM | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Up 2%Cytokinetics (NASDAQ:CYTK) Stock Price Up 2%May 28, 2024 | globenewswire.comCytokinetics Announces Closing of Public Offering of Common StockMay 28, 2024 | marketbeat.comJMP Securities Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $78.00JMP Securities cut their price objective on shares of Cytokinetics from $106.00 to $78.00 and set a "market outperform" rating on the stock in a research report on Tuesday.May 28, 2024 | markets.businessinsider.comBuy Rating Justified for Cytokinetics Amid Strong Capital Position and Promising Drug PipelineMay 28, 2024 | marketbeat.comNorges Bank Acquires Shares of 722,229 Cytokinetics, Incorporated (NASDAQ:CYTK)Norges Bank acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 722,229 shares of the biopharmaceutical company's stock, valuedMay 28, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) to Post Q2 2024 Earnings of ($1.05) Per Share, Leerink Partnrs ForecastsMay 28, 2024 | americanbankingnews.comHC Wainwright Comments on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)May 27, 2024 | finance.yahoo.comIs Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?May 27, 2024 | marketbeat.comHC Wainwright Weighs in on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceuticalMay 26, 2024 | uk.investing.comCytokinetics shares target cut, cites key financial transactionsMay 25, 2024 | marketbeat.comFranklin Resources Inc. Reduces Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Franklin Resources Inc. lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 41.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 660,682 shares of the biopharmaceMay 25, 2024 | americanbankingnews.comLeerink Partnrs Analysts Lower Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)May 25, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Stock Price Down 3% Following Analyst DowngradeMay 24, 2024 | seekingalpha.comCytokinetics Decides To Go It AloneMay 24, 2024 | marketbeat.comLeerink Partnrs Comments on Cytokinetics, Incorporated's FY2027 Earnings (NASDAQ:CYTK)Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Analysts at Leerink Partnrs cut their FY2027 earnings per share (EPS) estimates for Cytokinetics in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will earn $3May 24, 2024 | americanbankingnews.comNeedham & Company LLC Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $72.00May 24, 2024 | americanbankingnews.comBank of America Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $60.00May 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $70.00 at Raymond JamesMay 24, 2024 | americanbankingnews.comHC Wainwright Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $90.00May 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $95.00 at BarclaysMay 24, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Shares Gap Down on Analyst DowngradeMay 23, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising PipelineMay 23, 2024 | msn.comWhy Cytokinetics (CYTK) Shares Are FallingMay 23, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Price Target Lowered to $60.00 at Bank of AmericaBank of America cut their target price on shares of Cytokinetics from $70.00 to $60.00 and set a "neutral" rating for the company in a research report on Thursday.May 23, 2024 | marketwatch.comCytokinetics Shares Drop 17% After Public Offering PricesMay 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)May 23, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Gap Down After Analyst DowngradeCytokinetics (NASDAQ:CYTK) Shares Gap Down Following Analyst DowngradeMay 22, 2024 | globenewswire.comCytokinetics Announces Pricing of Public Offering of Common StockMay 22, 2024 | globenewswire.comCytokinetics Announces Proposed Public Offering of Common StockMay 22, 2024 | globenewswire.comCytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineMay 22, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from BrokeragesMay 22, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the comMay 21, 2024 | marketbeat.comTrexquant Investment LP Increases Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Trexquant Investment LP grew its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 411.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 109,810 shares of the biopharmaceutical company's stock after buying an additional 88,342 shares during theMay 20, 2024 | marketbeat.comBridger Management LLC Makes New $1.88 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)Bridger Management LLC bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 22,510 shares of the biopharmaceutical company's stock, valued at apMay 17, 2024 | msn.comCytokinetics to Host Muscle SeminarMay 17, 2024 | globenewswire.comCytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle BiologyMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Cytokinetics’ Aficamten Favorable Trial Data and Safety ProfileMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Alector (ALEC)May 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $65.96 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Charles Schwab Investment Management Inc. boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 789,969 shaMay 16, 2024 | marketbeat.comThornburg Investment Management Inc. Lowers Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Thornburg Investment Management Inc. lessened its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,199 shares of the bioMay 15, 2024 | globenewswire.comCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024May 14, 2024 | markets.businessinsider.comBuy Rating Justified: Cytokinetics’ Aficamten Shows Superior Efficacy in SEQUOIA-HCM Phase 3 TrialMay 14, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Cytokinetics (CYTK)May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Aficamten’s Positive Phase 3 Trial OutcomesMay 14, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of Cytokinetics in a report on Tuesday.May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Strong SEQUOIA-HCM Study Results and Favorable Market Prospects Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. CYTK Media Mentions By Week CYTK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.350.79▲Average Medical News Sentiment CYTK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼258▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Blueprint Medicines News Jazz Pharmaceuticals News Organon & Co. News Intra-Cellular Therapies News Viking Therapeutics News BridgeBio Pharma News Ascendis Pharma A/S News Ionis Pharmaceuticals News Madrigal Pharmaceuticals News Apellis Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
